Tildrakizumab for the treatment of plaque psoriasis in adults
Sign Up to like & getrecommendations! Published in 2019 at "Prescriber"
DOI: 10.1002/psb.1771
Abstract: Tildrakizumab (Ilumetri) is a new biological therapy targeting interleukin (IL)‐23 for the treatment of plaque psoriasis in adults. This article discusses its place in therapy and clinical trial efficacy. read more here.
Keywords: plaque psoriasis; psoriasis adults; treatment plaque;
Emerging systemic drugs in the treatment of plaque psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2020.1745773
Abstract: ABSTRACT Introduction Psoriasis is a common, chronic inflammatory skin condition that affects 2-3% of the US population and represents a large psychosocial burden for patients. Over the last decade, highly effective targeted therapies for psoriasis… read more here.
Keywords: treatment; mild disease; psoriasis; plaque psoriasis ... See more keywords
Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
Sign Up to like & getrecommendations! Published in 2019 at "Case Reports in Dermatology"
DOI: 10.1159/000501993
Abstract: Although available data are conflicting, psoriasis seems to be associated with an increased baseline risk of malignancy. In addition, some antipsoriatic systemic treatments have been associated with risk of malignancy. There is not enough data… read more here.
Keywords: secukinumab treatment; malignancy; psoriasis; plaque psoriasis ... See more keywords